Drug Profile
Eganelisib - Infinity Pharmaceuticals
Alternative Names: IPI-549Latest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Intellikine
- Developer Arcus Biosciences; Bristol-Myers Squibb; Infinity Pharmaceuticals; University of California, San Diego
- Class Amides; Amines; Antineoplastics; Isoquinolines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Urogenital cancer
Most Recent Events
- 28 Sep 2023 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)
- 28 Sep 2023 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Sep 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)